EGFR and non-small cell lung carcinoma: Based on these encouraging outcomes, ivonescimab has been approved in China in combination with chemotherapy for the treatment of EGFR-TKI-resistant SqCC and non-SqCC NSCLC, and is currently under priority review as a first-line monotherapy for PD-L1-positive NSCLC [192].